Introduction: Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) accompanies severe asthma in about 15% of the patients and may adversely affect the prognosis. Omalizumab and mepolizumab are biologics used in patients with severe asthma. The objective of this study is to assess the respiratory improvements. after these biologics in severe asthmatic pa... https://www.roneverhart.com/Liftmaster-K1D8387-1CC-Expansion-Circuit-Board/